Efectos de la administración de hidroxiurea en pacientes con necrosis avascular en anemia de células falciformes.
Palabras clave:
Anemia de células falciformes, Hidroxiurea, Osteonecrosis, Hemoglobinopatías, AntidrepanocíticosResumen
La hidroxiurea es un agente terapéutico utilizado en el tratamiento de la anemia de células falciformes o drepanocitosis. Esta patología es un trastorno genético autosómico recesivo. Su complicación más frecuente es la osteonecrosis, que afecta principalmente la epífisis de huesos largos como la cabeza y cóndilos femorales, cabeza humeral y la porción distal de la tibia. El objetivo del presente artículo es demostrar los efectos adversos de la administración de hidroxiurea en pacientes con necrosis avascular en anemia de células falciformes y exponer algunos tratamientos emergentes para esta patología. Para ello se realizó una revisión bibliográfica a través de las bases de datos de Pubmed y Elsevier de los últimos 10 años, sobre el fármaco utilizado para el tratamiento de la anemia de células falciformes y sí su administración conduce o no a la generación de la osteonecrosis. Como conclusión, se han descrito diversos efectos adversos ocasionados por la administración de hidroxiurea en pacientes con la patología mencionada.
Descargas
Referencias
Marahatta A, Ware RE. Hydroxyurea: Analytical techniques and quantitative analysis. Blood Cells Mol Dis. 2017; 67:135-42. doi: 10.1016/j.bcmd.2017.08.009
McGann PT, Ware RE. Hydroxyurea therapy for sickle cell anemia. Expert Opin Drug Saf. 2015;14(11):1749-58. doi: 10.1517/14740338.2015.1088827
Zúñiga C P, Martínez G C, González R LM, Rendón C DS, Rojas R N, et al. Enfermedad de células falciformes: Un diagnóstico para tener presente. Rev Chil Pediatr. 2018;89(4):525-29.
Ortega Aramburu JJ. Anemia de células falciformes: una enfermedad emergente en España. An Pediatr (Barc). 2003;58(2):93-4.
Hernigou P. Ostéonécrose de la tête fémorale [Hip osteonecrosis]. Rev Prat. 2020;70(4):409-15. French.
Lespasio MJ, Sodhi N, Mont MA. Osteonecrosis of the Hip: A Primer. Perm J. 2019;23:18-100. doi: 10.7812/TPP/18-100
Azmet FR, Al-Kasim F, Alashram WM, Siddique K. The role of hydroxyurea in decreasing the occurrence of vasso-occulusive crisis in pediatric patients with sickle cell disease at King Saud Medical City in Riyadh, Saudi Arabia. Saudi Med J. 2020;41(1):46-52. doi: 10.15537/smj.2020.1.24698
Burgos Luna JM, Páez Rúa DM, Ruiz Ordoñez I, Fernández PA, Escobar Vidarte MF. Description of criteria for near miss in high-complexity obstetric population with sickle cell anemia: an observational study. J Matern Fetal Neonatal Med. 2020;33(6):941-6. doi: 10.1080/14767058.2018.1510912
Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;86(6):480-7. doi: 10.2471/blt.06.036673
Adekile AD, Gupta R, Al-Khayat A, Mohammed A, Atyani S, Thomas D. Risk of avascular necrosis of the femoral head in children with sickle cell disease on hydroxyurea: MRI evaluation. Pediatr Blood Cancer. 2019;66(2):e27503. doi: 10.1002/pbc.27503
Kato GJ, Hebbel RP, Steinberg MH, et al. Vasculopathy in sickle cell disease: biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol. 2009;84:618-25. doi: 10.1002/ajh.21475
Morris CR. Mechanisms of vasculopathy in sickle cell disease and thalassemia. Hematology Am Soc Hematol Educ Program. 2008;2008:177- 85. doi: 10.1182/asheducation-2008.1.177
Adesina OO, Neumayr LD. Osteonecrosis in sickle cell disease: an update on risk factors, diagnosis, and management. Hematology Am Soc Hematol Educ Program. 2019;2019(1):351-8. doi: 10.1182/hematology.2019000038
Naseer ZA, Bachabi M, Jones LC, Sterling RS, Khanuja HS. Osteonecrosis in Sickle Cell Disease. South Med J. 2016;109(9):525-30. doi: 10.14423/SMJ.0000000000000516
Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, Smith WR, Panepinto JA, Weatherall DJ, Costa FF, Vichinsky EP. Sickle cell disease. Nat Rev Dis Primers. 2018; 4:18010.
Sundd P, Gladwin MT, Novelli EM. Pathophysiology of Sickle Cell Disease. Annu Rev Pathol. 2019;14:263-92. doi: 10.1146/annurev-pathmechdis-012418-012838
Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet. 2017;390(10091):311-23. doi: 10.1016/S0140-6736(17)30193-9
Vanderhave KL, Perkins CA, Scannell B, Brighton BK. Orthopaedic Manifestations of Sickle Cell Disease. J Am Acad Orthop Surg. 2018;26(3):94-101. doi: 10.5435/JAAOS-D-16-00255
Pijnenburg L, Felten R, Javier RM. Ostéonécroses aseptiques, une revue générale des ostéonécroses de la hanche, et au-delà [A review of avascular necrosis, of the hip and beyond]. Rev Med Interne. 2020;41(1):27-36. French.
Vaishya R, Agarwal AK, Edomwonyi EO, Vijay V. Musculoskeletal Manifestations of Sickle Cell Disease: A Review. Cureus. 2015;7(10):e358. doi: 10.7759/cureus.358
Venkataraman A, Adams RJ. Neurologic complications of sickle cell disease. Handb Clin Neurol. 2014;120:1015-25. doi: 10.1016/B978-0-7020-4087-0.00068-1
Petek D, Hannouche D, Suva D. Osteonecrosis of the femoral head: pathophysiology and current concepts of treatment. EFORT Open Rev. 2019 ;4(3):85-97. doi: 10.1302/2058-5241.4.180036
Lee GC, Khoury V, Steinberg D, Kim W, Dalinka M, Steinberg M. How do radiologists evaluate osteonecrosis? Skeletal Radiol. 2014;43(5):607-14. doi: 10.1007/s00256-013-1803-4
Worrall D, Smith-Whitley K, Wells L. Hemoglobin to Hematocrit Ratio: The Strongest Predictor of Femoral Head Osteonecrosis in Children With Sickle Cell Disease. J Pediatr Orthop. 2016;36(2):139-44. doi: 10.1097/BPO.0000000000000409
Oliveira EAM, Boy KA, Santos APP, Machado CDS, Velloso-Rodrigues C, Gerheim PSAS, Mendonça LM. Evaluation of hydroxyurea genotoxicity in patients with sickle cell disease. Einstein (Sao Paulo). 2019;17(4):eAO4742. doi: 10.31744/einstein_journal/2019AO4742
Schuchard SB, Lissick JR, Nickel A, Watson D, Moquist KL, Blaylark RM, Nelson SC. Hydroxyurea use in young infants with sickle cell disease. Pediatr Blood Cancer. 2019;66(7):e27650. doi: 10.1002/pbc.27650
Dong M, McGann PT, Mizuno T, Ware RE, Vinks AA. Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia. Br J Clin Pharmacol 2016;81:742-52. doi: 10.1111/bcp.12851
Zahran AM, Nafady A, Saad K, Hetta HF, Abdallah AM, Abdel-Aziz SM, Embaby MM, Abo Elgheet AM, Darwish SF, Abo-Elela MGM, Elhoufey A, Elsayh KI. Effect of Hydroxyurea Treatment on the Inflammatory Markers Among Children With Sickle Cell Disease. Clin Appl Thromb Hemost. 2020;26:1076029619895111. doi: 10.1177/1076029619895111
Adekile AD, Gupta R, Al-Khayat A, Mohammed A, Atyani S, Thomas D. Risk of avascular necrosis of the femoral head in children with sickle cell disease on hydroxyurea: MRI evaluation. Pediatr Blood Cancer. 2019;66(2):e27503. doi: 10.1002/pbc.27503
Lemonne N, Charlot K, Waltz X, Ballas SK, Lamarre Y, Lee K, et al. Hydroxyurea treatment does not increase blood viscosity and improves red blood cell rheology in sickle cell anemia. Haematologica. 2015;100(10):e383-6. doi: 10.3324/haematol.2015.130435
Lemonne N, Möckesch B, Charlot K, Garnier Y, Waltz X, Lamarre Y, Antoine-Jonville S, Etienne-Julan M, Hardy-Dessources MD, Romana M, Connes P. Effects of hydroxyurea on blood rheology in sickle cell anemia: A two-years follow-up study. Clin Hemorheol Microcirc. 2017;67(2):141-8. doi: 10.3233/CH-170280
Thornburg CD, Files BA, Luo Z, Miller ST, Kalpatthi R, Iyer R, et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood. 2012; 120(22):4304-10. doi: 10.1182/blood-2012-03-419879
Luchtman-Jones L, Pressel S, Hilliard L, Brown RC, Smith MG, Thompson AA, et al. Effects of hydroxyurea treatment for patients with hemoglobin SC disease. Am J Hematol. 2016;91(2):238-42. doi: 10.1002/ajh.24255
Karimi M, Cohan N, Mousavizadeh K, Falahi MJ, Haghpanah S. Adverse effects of hydroxyurea in beta-thalassemia intermedia patients: 10 years’ experience. Pediatr Hematol Oncol. 2010;27(3):205-11. doi: 10.3109/08880011003639952
Ballas SK, McCarthy WF, Guo N, DeCastro L, Bellevue R, Barton BA, et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. J Natl Med Assoc. 2009;101(10):1046-51. doi: 10.1016/s0027-9684(15)31072-5
Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood. 2010;115(12):2354-63. doi: 10.1182/blood-2009-05-221333
Carden MA, Little J. Emerging disease-modifying therapies for sickle cell disease. Haematologica. 2019;104(9):1710-19. doi: 10.3324/haematol.2018.207357
Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 2014;312:1033-48. doi: 10.1001/jama.2014.10517
Inusa BPD, Hsu LL, Kohli N, Patel A, Ominu-Evbota K, Anie KA, et al. Sickle Cell Disease-Genetics, Pathophysiology, Clinical Presentation and Treatment. Int J Neonatal Screen. 2019;5(2):20. doi: 10.3390/ijns5020020
Murad M, Hazem A, Prokop L. Hydroxyurea for Sickle Cell Disease: A Systematic Review of Benefits, Harms, and Barriers of Utilization, 2012 Prepared for the National Heart, Lung, and Blood Institute (NHLBI) Prepared by the Knowledge and Encounter Research Unit. Mayo Clin. 2012;2012:1-116
Steinberg M, Barton F, Castro O, Pegelow C, Ballas S, Kutlar A, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. JAMA. 2003;289:1645-51. doi: 10.1001/jama.289.13.1645
Inati A. Recent advances in improving the management of sickle cell disease. Blood Rev. 2009;23:S9-S13. doi: 10.1016/S0268-960X(09)70004-9
Adewoyin A, Obieche J. Hypertransfusion therapy in sickle cell disease in Nigeria. Adv. Hematol. 2014;2014:923593. doi: 10.1155/2014/923593
Paikari A, Sheehan VA. Fetal haemoglobin induction in sickle cell disease. Br J. Haematol. 2018;180(2):189-200. doi: 10.1111/bjh.15021
Molokie R, Lavelle D, Gowhari M, Pacini M, Krauz L, Hassan J, et al. Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study. PLoS Med. 2017;14(9):e1002382. doi: 10.1371/journal.pmed.1002382
Reid ME, El Beshlawy A, Inati A, Kutlar A, Abboud MR, Haynes J Jr, et al. A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. Am J Hematol. 2014;89(7):709-13. doi: 10.1002/ajh.23725
Cui S, Lim KC, Shi L, Lee M, Jearawiriyapaisarn N, Myers G, et al. The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice. Blood. 2015;126(3):386-96. doi: 10.1182/blood-2015-02-626259
Zhang Y, Paikari A, Sumazin P, Ginter Summarell CC, Crosby JR, Boerwinkle E, et al. Metformin induces FOXO3-dependent fetal hemoglobin production in human primary erythroid cells. Blood. 2018;132(3):321-33. doi: 10.1182/blood-2017-11-814335
Heeney M, Hoppe C, Abboud M, Inusa B, Kanter J, Ogutu B, et al. A multinational trial of prasugrel for sickle cell vaso-occlusive events. N. Engl. J. Med. 2016;374:625-635. doi: 10.1056/NEJMoa1512021
Hoppe C, Styles L, Heath L, Zhou C, Jakubowski J, Winters K, et al. Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global Phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy. Pediatr. Blood Cancer. 2016;63:299-305. doi: 10.1002/pbc.25771
Telen M. Beyond hydroxyurea: New and old drugs in the pipeline for sickle cell disease. Blood. 2016;127:810-9. doi: 10.1182/blood-2015-09-618553
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2023 Salutem Scientia Spiritus
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
La Revista Salutem Scientia Spiritus usa la licencia Creative Commons de Atribución – No comercial – Sin derivar: Los textos de la revista son posibles de ser descargados en versión PDF siempre que sea reconocida la autoría y el texto no tenga modificaciones de ningún tipo.
